First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.
- DOI
- 10.1080/14737140.2024.2373888
- Published
- 2024 Sep
- Container
- Expert review of anticancer therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737140.2024.2373888,
title = {First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.},
author = {Peterlin P and Saada-Bouzid E and Moskovitz M and Pigneux A and Yuda J and Sinnollareddy M and Henner WR and Chen D and Freise KJ and Leibman RS and Avigdor A and Shimizu T},
year = {2024},
journal = {Expert review of anticancer therapy},
doi = {10.1080/14737140.2024.2373888},
url = {https://doi.org/10.1080/14737140.2024.2373888}
}RIS
TY - JOUR TI - First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. AU - Peterlin P AU - Saada-Bouzid E AU - Moskovitz M AU - Pigneux A AU - Yuda J AU - Sinnollareddy M AU - Henner WR AU - Chen D AU - Freise KJ AU - Leibman RS AU - Avigdor A AU - Shimizu T PY - 2024 JO - Expert review of anticancer therapy DO - 10.1080/14737140.2024.2373888 UR - https://doi.org/10.1080/14737140.2024.2373888 ER -
APA
P, P., E, S., M, M., A, P., J, Y., M, S., WR, H., D, C., KJ, F., RS, L., A, A., & T, S. (2024). First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.. Expert review of anticancer therapy. https://doi.org/10.1080/14737140.2024.2373888
Source records
- pubmed · retrieved 2026-09-26T07:12:19.764Z